Figure 1. Serum levels of soluble urokinase-type plasminogen activator receptor (suPAR) in the control group, as well as in the acute exacerbation of COPD (AECOPD) group on day 1 and after 14 days of treatment.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.